<a id="bm-comp-97d36bf5-dfee-4723-bbbb-609593a46b9a" name="bm-comp-97d36bf5-dfee-4723-bbbb-609593a46b9a" class="BMCustomAnchor"></a><table><tr><td bm-component-id="97d36bf5-dfee-4723-bbbb-609593a46b9a" style="vertical-align: top; width:100.000000%;"><ul><li>24% organic sales growth in Q4 (ABGSCe +27%)</li><li><font style="background-color:#ffffff;">Adj. EBIT -2</font><font style="background-color:#ffffff;">% vs ABGSCe</font></li><li><font style="background-color:#ffffff;">No change in outlook</font></li></ul></td></tr></table><a id="bm-comp-bde97b72-6ef2-4755-a035-6cb58c37afcf" name="bm-comp-bde97b72-6ef2-4755-a035-6cb58c37afcf" class="BMCustomAnchor"></a><table><tr><td bm-component-id="bde97b72-6ef2-4755-a035-6cb58c37afcf" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3"><font style="background-color:#ffffff;">Q4 results</font></h3><p><font style="background-color:#ffffff;">OssDs</font>ign reported <font style="background-color:#ffffff;">a mixed set of numbers in Q4 with lower sales but higher gross margin and good cost control. Q4 sales came in at SEK 45.1m (-5% vs ABGSCe SEK 47.3m, no consensus) and adj. EBIT of SEK -9.4m, -2% vs ABGSCe of -9.2m. The miss on adj. EBIT is attributable to lower sales as core opex came in better and gross was higher at 96.3% in Q4 (vs ABGSCe 95.5%). We are pleased to see that the 'sales and commission and fees' as percentage of sales continues to come down, was 47.6% in Q4 vs ABGSCe at 51.5%). Q4 reported EBIT was negatively impacted by CEO transition costs of SEK 12m (ABGSCe SEK 0m), booked as NRI. Organic sales growth in Q4 amounted to 24% (ABGSCe 27%).</font></p><p><font style="background-color:#ffffff;">Webcast at 11.00 CET today, link:</font> <a href="https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.finwire.tv%2Fwebcast%2Fossdsign%2Fq4-2025%2F&data=05%7C02%7Csten.gustafsson%40abgsc.se%7C27e5d94e9da4478bc00b08de62e98548%7C853e8b8340544eb98b26ec6513dd213d%7C0%7C0%7C639056952573867207%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=Mu8A0N6JE8aUPnbE1s15SpJMEsD8xE08YrUABejz7sc%3D&reserved=0" style="color:#0c6389; text-decoration:none;"><u><font color="#0000ff">https://www.finwire.tv/webcast/ossdsign/q4-2025/</font></u></a></p><h3 class="bm-h3">Estimates</h3><p>Company is not providing any outlook for 2026 or changing its mid-term financial targets of reaching sales of SEK >400m by 2028 and to become cash flow and EBIT positive in the s<font style="background-color:#ffffff;">econd half of its 'Strategy Period' (2025-2028). Based on the deviation on adj EBIT in Q4, we expect FY'26e adj. EBIT to be revised down by mid- to high single digit.</font></p><h3 class="bm-h3"><font style="background-color:#ffffff;">Share price view</font></h3><p><font style="background-color:#ffffff;">The stock has been soft into Q4, down 2-3% (-5d) and down weak YTD (-15%). Based on the miss on sales and deviation on adj EBIT, we expect to see a small negative share price reaction in similar magnitude as the estimated earnings revisions.</font></p><br /><br /><table id="bm-img-5858e612-cbc0-4c72-83a8-074d9d96a66a" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">Q4 deviation table</td></tr><tr><td><img bm-img-encrypt="5858e612-cbc0-4c72-83a8-074d9d96a66a" bm-img-original-height="589" bm-img-original-width="965" bm-img-svg="image:image_upload/93557_19ea8933-5e07-4e42-ade6-3b433d42ced9.svg" bm-img-width-hint="100%" id="bm-id-28287531-5e76-4aab-bdd1-0e4f57f2ee92" src="https://abgsc.bluematrix.com/images/image_upload/93557_19ea8933-5e07-4e42-ade6-3b433d42ced9_733.png" svg="/nas/web/clients/abgsc/images/image_upload/93557_19ea8933-5e07-4e42-ade6-3b433d42ced9.svg" width="727" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: ABG Sundal Collier, Company data</td></tr></table></td></tr></table>